A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Change From Baseline (in Parent Study) in Eczema Area and Severity Index (EASI) Score at Each Visit

Time frame: Baseline, Up to 6 years

Percent Change From Baseline (in Parent Study) in EASI Score at Each Visit

Time frame: Baseline, Up to 6 years

Percentage of Participants With EASI-50 at Each Visit

Time frame: Up to 6 years

Percentage of Participants with EASI-75 at Each Visit

Time frame: Up to 6 years

Percentage of Participants with EASI-90 at Each Visit

Time frame: Up to 6 years

Percentage of Participants who Achieve Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) of Clear (0) or Almost clear (1) at Each Visit

Time frame: From Baseline up to 6 years

Change from Baseline (in the parent study) in Participant-Oriented Eczema Measure (POEM) at Each Visit

Time frame: Baseline, Up to 6 years

Change from Baseline (in the parent study) in Dermatology Life Quality Index (DLQI) at Each Visit

Time frame: Baseline, Up to 6 years

Serum Concentration of Afimkibart at Specified Timepoints

Time frame: Pre-dose on Day 1, Weeks 2, 10, 18, 26, 34, 42, 50 74, 98, 122, 146, 170, 194, 218, 242, 266, 290 and 14 weeks after last dose